+ Watch FHCO
on My Watchlist
The Female Health Company engages in the manufacture, marketing, and distribution of the female condom.
sell the female condom. distributed abroad. massive free cash flow.
The price of FHCO is in decline since their last earnings release. What people seem to forget, and what FHCO management is constantly repeating, is that their income fluctuates immensely due to the spending patterns of governments and NGO's. Despite lower reported earnings there is NO decrease in demand, it is just the cycle.I therefore see this as an amazing opportunity to make us of irrational behavior by investors. This company has a tremendously strong balance sheet. My intrinsic value estimate is $12.
Long. 14x fye. 21% rev growth. Female condoms.
Management owns a big slice of the pie, here. They keep voting themselves new dividends. Sales of female condoms are increasing in the developing world.
This company has a great yield, low P/E and is solving a global problem.
Low debt, unique and needed product, unbelievable ROI. reasonable to low PE, and it pays a dividend with a payout of less than 50%. It's a no-brainer for me.
Seems to be a fundamentally sound company, though the reliance on government and NGO income means I won't be adding it to my portfolio.
Decent financials, consumable product, lots of growth potential not only in industrializing countries, but in already-industrialized countries. That's a rare treat these days.
Top 25 best company pick
There is a defintie need for theior producct which will continue for quite a while.
underdeveloped nations need this
This has been a steady performer, bit it is still cheap. It also helps to have a product that is revolutionary.
During the London Summit in 2012, the Female Health Company announced a program to support the London Summit's goal to provide contraceptives to an additional 120 million women by 2020. This program includes a plan for the company to invest up to $14 million over the next six years in reproductive health and HIV/AIDS prevention education and training in collaboration with global agencies.
I just bought this in real life. The reasons I bought are:- Debt free balance sheet- Company has strong margins and produces healthy free cash flow. They even produced FCF in 2011 when their sales were way down due to some big orders that were delayed until 2012.- Very little (if any) competition. They have the only FDA approved product.- They have US and UK tax-loss carry forwards that will benefit net income.- Demand is increasing and they just completed an expansion of their production facility.A company that has a nice moat in a niche that should continue to grow, a strong balance sheet, and only one analyst following it. All that for 16x trailing earnings? I'm in. Peter Lynch would be proud.
It's a World Health Organization play. Not to worry about fundamentals, rather big public funding to spread their product around the 3rd world.
A fun stock to have when the time is right!!
Population growth but with moderation as compared to the past because having children is becoming a more important financial matter in everyday family.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions